Hoth Therapeutics Achieves Breakthrough In Phase 2a HT-001 Trial Delivering 100% Success in Combating Cancer Treatment Skin Toxicities; 100% Of Patients In Cohort 1 Achieve Primary Efficacy Endpoint

• 100% of Patients in Cohort 1 Achieve Primary Efficacy Endpoint
• No Treatment-Related Adverse Effects Observed
• Preserves Cancer Treatment Efficacy with Zero Dose Reductions

NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a leading biopharmaceutical company focused on patient-centric solutions, today shared encouraging interim safety and efficacy results from its Phase 2a clinical trial of HT-001, designed to address skin toxicities linked to Epidermal Growth Factor Receptor Inhibitors (EGFRi) in cancer patients.

Exceptional Patient Outcomes:

Data from the open-label portion of the CLEER-001 trial demonstrated remarkable success:

• 100% of patients achieved the primary efficacy endpoint of an ARIGA score ≤1, showing significant skin toxicity improvement by the six-week mark.
• 66% of patients reported reduced pain and itching scores, further enhancing quality of life.

Crucially, all patients maintained their full EGFRi dosage, preserving the cancer treatment's full therapeutic effect—a notable improvement compared to past reports showing widespread dose reductions or treatment halts due to skin-related side effects.